Trial Profile
A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2024
Price :
$35
*
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 06 Feb 2024 Planned End Date changed from 1 Mar 2023 to 1 Feb 2025.
- 06 Feb 2024 Planned primary completion date changed from 1 Mar 2023 to 20 Mar 2024.
- 27 Mar 2023 Planned End Date changed from 1 Dec 2019 to 1 Mar 2023.